Peptides and aptamers thereof as specific modulators of mutant p53 function

2-5. (canceled)

A nucleic acid encoding a molecule comprising a peptide capable to bind contact and conformational p53 mutants and isoforms thereof within the region corresponding to the wild-type p53 (GenBank No ABB80262) DNA binding core domain comprised from amino acids 74 to amino acids 298 sequence, wherein said peptide is selected in the group consisting of peptides having the sequences AKYCQCAAKVRVTAAM (Seq.ID.No:1). GPVVPRTOYMSLAFGW (Seq. MN 2). IQITLTGWSARVTTSG (Seq.ID.No:

• 3). VWAESCDDCGEYWRYV (Seq.ID.No:4). DVADWESCGEYWCYRV (Seq.ID.No:5), OAGSGREKCQHAAYLS (Seq.ID.No:6). ARTDTAVVHVCDSGRQ (Seq.ID.No:7), QQSRGRCPSCIPEAAS (Seq.ID.No:8). PGKLIRVSENMSSALG (Seq.ID.No:9). TPEGLDVALAVAAYSV (Seq.ID.No:
• 10).

A pharmaceutical composition comprising as active principle at least one molecule according to any one of the claims from 1 to 8 in combination with pharmaceutically acceptable excipients, diluents and/or delivery systems of the active principle, wherein said composition is for systemic and/or local administration.

(canceled)

A method for treating a subject in a need of antitumoral therapy comprising the administration of a molecule comprising a peptide capable to bind contact and conformational p53 mutants and isoforms thereof within the region corresponding to the wild-type p53 (GenBank No ABB80262) DNA binding core domain comprised from amino acids 74 to amino acids 298 sequence, wherein said peptide is selected in the group consisting of peptides having the sequences AKYCQCAAKVRVTAAM (Seq.ID.No:1), GPVVPRTQYMSLAFGW (Seq. IDN 2). IQITLTGWSARVTTSG (Seq.ID.No:

• 3), VWAESCDDCGEYWRYV (Seq.ID.No:4), DVADWESCGEYWCYRV (Seq.ID.No:5), QAGSGREKCQHAAYLS (Seq.ID.No:6), ARTDTAVVHVCDSGRQ (Seq.ID.No:7), QQSRGRCPSCIPEAAS (Seq.ID.No:8), PGKLIRVSENMSSALG (Seq.ID.No:9), TPEGLDVALAVAAYSV (Seq.ID.No:
• 10).

22-23. (canceled)

25-26. (canceled)

A method for detection of structural and conformational p53 mutants in isolated cells or tissues, comprising the use of a molecule comprising a peptide capable to bind contact and conformational p53 mutants and isoforms thereof within the region corresponding to the wild-type p53 (GenBank No ABB80262) DNA binding core domain comprised from amino acids 74 to amino acids 298 sequence, wherein said peptide is selected in the group consisting of peptides having the sequences AKYCQCAAKVRVTAAM (Seq.ID.No:1), GPVVPRTQYMSLAFGW (Seq. IDN 2), IQITLTGWSARVTTSG (Seq.ID.No:

• 3), VWAESCDDCGEYWRYV (Seq.ID.No:4), DVADWESCGEYWCYRV (Seq.ID.No:5), QAGSGREKCQHAAYLS (Seq.ID.No:6), ARTDTAVVHVCDSGRQ (Seq.ID.No:7), QQSRGRCPSCEPEAAS (Seq.ID.No:8), PGKLIRVSENMSSALG (Seq.ID.No:9), TPEGLDVALAVAAYSV (Seq.ID.No:
• 10).

A kit for the diagnosis of structural or conformational p53 mutants bearing tumors comprising at least one molecule comprising a peptide capable to bind contact and conformational p53 mutants and isoforms thereof within the region corresponding to the wild-type p53 (GenBank No ABB80262) DNA binding core domain comprised from amino acids 74 to amino acids 298 sequence. wherein said peptide is selected in the group consisting of peptides having the sequences AKYCQCAAKVRVTAAM (Seq.ID.No:1), GPVVPRTQYMSLAFGW (Seq. IDN 2), IQITLTGWSARVTTSG (Seq.ID.No:

• 3), VWAESCDDCGEYWRYV (Seq.ID.No:4), DVADWESCGEYWCYRV (Seq.ID.No:5), QAGSGREKCQHAAYLS (Seq.ID.No:6), ARTDTAVVHVCDSGRQ (Seq.ID.No:7), QQSRGRCPSCIPEAAS (Seq.ID.No:8), PGKLIRVSENMSSALG (Seq.ID.No:9), TPEGLDVALAVAAYSV (Seq.ID.No:
• 10) as reagents.

A peptido-mimetic compound comprising one or more amino acids which bind by polar or hydrophobic interactions contact and conformational p53 mutants and isoforms thereof within the region corresponding to the wild-type p53 (GenBank No ABB80262) DNA binding core domain comprised from amino acids 74 to amino acids 298 sequence.